Cargando…
Treatment of castration-resistant prostate cancer and bone metastases with radium-223 dichloride
Radium-223 dichloride (Ra-223) is the first α-particle emitting radiopharmaceutical to be approved for the treatment of patients with castration-resistant prostate cancer and associated bone metastases, and the first bone-targeting agent to significantly improve patient overall survival whilst reduc...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Blackwell Publishing Ltd
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467240/ https://www.ncbi.nlm.nih.gov/pubmed/26097500 http://dx.doi.org/10.1111/ijun.12059 |